Prior to the ICER meeting to review evidence and vote on cost-effectiveness ratings for NSCLC treatments, five prominent oncologists...

I have extensive experience in “real world” policy-setting and decision-making and I am puzzled about the motivations regarding the...

McGivney Global Advisors publishes quarterly reports  assessing the changes and impact of Oncology Value Metrics, including NCCN Evidence...